Different studies revealed that the medication LCZ696 slows down the course of DCM by blocking apoptosis via the AGEs/NF-κB and PERK/CHOP signaling pathways, suggesting that it may be useful as a therapy [144]. This evidence concerns the gene NFKB1 and familial dilated cardiomyopathy.